Regeneronvs.Vertex Pharmaceuticals
REGN vs VRTX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Vertex Pharmaceuticals is about 1.7× larger than Regeneron by market cap; Regeneron trades at the lower P/E (15.7 vs 27.9); year to date, Vertex Pharmaceuticals leads (+7.1% vs −13.9%).
Side by side
| REGN | VRTX | |
|---|---|---|
| Market cap | $69.7B | $121B |
| Price | $664.52 | $485.39 |
| Today | −0.5% | −2.2% |
| Return YTD | −13.9% | +7.1% |
| Return 1Y | +18.7% | +1.2% |
| P/E | 15.7 | 27.9 |
| P/S | 4.7 | 9.9 |
| P/B | 2.2 | 6.3 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
RegeneronREGN
American biotech company focused on antibody-based medicines in ophthalmology, immunology and oncology.
Full REGN profile →Vertex PharmaceuticalsVRTX
American biotech company and global leader in cystic fibrosis treatment, with a pipeline in pain and gene therapy.
Full VRTX profile →More comparisons in Biotech & innovation
See where REGN and VRTX sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →